IN-DATE
MN1620: Bard Magnum Biopsy Needle 16G x 20cm
Photos are for illustration purposes only and may not depict the exact item.
Sign in to add this product to your favorites!
| Price: | $199.00 per box of 10 |
|---|---|
| Quantity: | |
| In Stock: | 5 box of 10 |
| Expiration: | 06-2028 |
Additional Details
BD Bard Magnum Core Biopsy System
- Small size and lightweight give you better handling and control
- High velocity throw and precise needle design contribute to consistent, high quality samples
- Penetration depths of 15mm or 22mm
- Compatibility with Bard® TruGuide® Coaxial Biopsy Needle enhances efficiency and accuracy
AccessGUDID Info
- FDA Product Code: FCG
- FDA Product Code Name: Biopsy needle
- GMDN Term Code: 64328
- GMDN Term Name: Side-notch biopsy gun needle
- GMDN Term Description: An invasive tubular surgical instrument designed to be connected to a biopsy gun handpiece (not included) for the automatic extraction of a small tissue sample from an anatomical structure (a biopsy), while causing minimal surrounding tissue damage, for tissue pathological examination/testing. It is a percutaneously-inserted needle with a side-notch cutter at the distal end which when activated causes a sharp, sliding cannula to slice a segment of tissue. It is typically used to obtain samples of soft tissue from the kidneys, prostate, pancreas, liver, and breast, often performed under image guidance. This is a single-use device.
Manufacturer
C.R. Bard (a part of BD - Becton, Dickinson and Company) was a global leader in the development and manufacturing of innovative medical technologies. Known for their high-quality products, Bard specialized in solutions for vascular access, urology, oncology, and surgical specialties. Their product portfolio included catheters, biopsy devices, implantable ports, and hernia repair systems, designed to enhance patient care and procedural efficiency. As part of BD, the legacy of C.R. Bard continues to drive advancements in healthcare, delivering trusted solutions that improve outcomes for patients and providers worldwide.
